Oncolytic virus VG161 brings new hope for advanced HCC

Abstract

The study titled “Oncolytic virus VG161 in refractory hepatocellular carcinoma” presents a promising advancement in third-line therapy for advanced hepatocellular carcinoma (HCC). VG161, derived from an oncolytic herpes simplex virus, is engineered to express interleukin (IL)-12, IL-15, IL-15R, and a fusion protein that blocks the programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) pathway. In the multicenter phase 1 clinical trial, VG161 exhibited both strong efficacy and safety. This paper summarizes the study’s findings, discusses potential limitations, and proposes directions for future research.

Keywords

Advanced HCC / oncolytic virus / TME

References

[1] Forner A,Bruix J.Hepatocellular carcinoma.Lancet2018;391:1301-14

[2] Ding L,Yang W.Deciphering diverse cell-death patterns to predict the prognosis and potential therapy target of hepatocellular carcinoma patients.View2025;20240105

[3] Llovet JM,Mazzaferro V.Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008;359:378-90

[4] Heo J,Ruo L.Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.Nat Med2013;19:329-36

[5] Shen Y,Zhang Q.Oncolytic virus VG161 in refractory hepatocellular carcinoma.Nature2025;641:503-11

[6] Todo T,Ino Y.Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.Nat Med2022;28:1630-9 PMCID:PMC9388376

[7] Tan AT,Jin J.Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC.Hepatol Commun2022;6:841-54

[8] Chaurasiya S,Kang S.Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.Oncoimmunology2020;9:1729300

[9] Schweitzer A,Mikolajczyk RT,Ott JJ.Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.Lancet2015;386:1546-55

[10] Opio CK,Kirkpatrick P.Entecavir.Nat Rev Drug Discov2005;4:535-6

[11] Summers J.Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate.Cell1982;29:403-15

[12] Muylaert I,Elias P.Replication and recombination of herpes simplex virus DNA.J Biol Chem2011;286:15619-24

[13] Lamontagne RJ,Bouchard MJ.Hepatitis B virus molecular biology and pathogenesis.Hepatoma Res2016;2:163-86 PMCID:PMC5198785

[14] Zou W,Chen L.PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations.Sci Transl Med2016;8:328rv4 PMCID:PMC4859220

[15] Li Q,Yang Y.PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.Front Immunol2022;13:1070961 PMCID:PMC9806143

[16] Sun Y,Zhong Y.Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma.Cell2021;184:404-21.e16

[17] Warricker F,Blunt MD.The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma.J Transl Genet Genom2021;5:304-22 PMCID:PMC7612080